The drug’s ability to inhibit casein kinase 1 ε (CK1ε) and the human anterior gradient protein 2 homolog (AGR2) may contribute to its efficacy in inducing cell cycle arrest and apoptosis in bladder cancer cells. Here, AGR2 is linked to urinary bladder cancer.